WealthCollab’s Aprea Therapeutics APRE Stock Holding History

WealthCollab’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$127	Hold	158	–	–	﹤0.01%	962
2026 Q1	$121	Hold	158	–	–	﹤0.01%	966
2025 Q4	$135	Hold	158	–	–	﹤0.01%	1011
2025 Q3	$234	Hold	158	–	–	﹤0.01%	964
2025 Q2	$268	Hold	158	–	–	﹤0.01%	934
2025 Q1	$323	Hold	158	–	–	﹤0.01%	895
2024 Q4	$520	Hold	158	–	–	﹤0.01%	848
2024 Q3	$435	Hold	158	–	–	﹤0.01%	861
2024 Q2	$644	Hold	158	–	–	﹤0.01%	828
2024 Q1	$1.06K	Hold	158	–	–	﹤0.01%	817
2023 Q4	$743	Buy	+158	New	+$647	﹤0.01%	846

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

WealthCollab's APRE Position: Q2 2026 in Review

WealthCollab held its Aprea Therapeutics (APRE) position steady in Q2 2026 at 158 shares worth $127. The position accounts for ﹤0.01% of the portfolio, ranked #962.

WealthCollab first reported a position in APRE in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.06K in Q1 2024. 27 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

WealthCollab held 158 shares of Aprea Therapeutics worth $127 as of Q2 2026.
WealthCollab left its Aprea Therapeutics share count unchanged in Q2 2026.
Aprea Therapeutics made up ﹤0.01% of WealthCollab's portfolio in Q2 2026, its #962 holding.
WealthCollab first reported a position in Aprea Therapeutics in Q4 2023 and has held it in 11 quarters since.
WealthCollab's Aprea Therapeutics position peaked at $1.06K in Q1 2024.
27 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on WealthCollab's 13F filing for Q2 2026, filed 10 Aug 2026.